Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen announced that its clinical program for fasedienol nasal spray has achieved the minimum patient exposures recommended under ICH E1 for long-term treatment of non-life-threatening conditions. As of May 31, 2026, over 1,500 subjects have received at least a single exposure, with over 300 subjects exposed for at least 6 months and over 100 for at least 12 months.
Key figures
- Drug Name
- fasedienol
- Phase Of Trial
- Phase 3
- Total subjects exposed
- 1500
- Subjects 6 month exposure
- 300
- Subjects 12 month exposure
- 100
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.